Literature DB >> 27427214

Outcome of resection of WHO Grade II meningioma and correlation of pathological and radiological predictive factors for recurrence.

Anil Nanda1, Shyamal C Bir2, Subhas Konar2, Tanmoy Maiti2, Piyush Kalakoti2, Jamie A Jacobsohn3, Bharat Guthikonda2.   

Abstract

This study investigated whether extent of surgical resection (Simpson and Shinshu grade) along with pathological and radiological factors influence the tumor control and recurrence-free survival (RFS) of patients with World Health Organization (WHO) grade II meningiomas. The clinical, radiological and surgical notes on the 59 patients with WHO grade II meningioma managed at our institution over 20years were retrospectively reviewed. In this study, median survival time was 41months. The overall recurrence rate in Simpson grades I and II resection was 31%. In grades III and IV, the overall recurrence rate was 73%, and this high recurrence rate in these groups was confined within 5years. In Cox regression analysis, combined data of grades (I and II)/complete resection showed a significant difference in RFS compared to grades (III and IV)/subtotal resection (p=0.0001). A similar trend of RFS (p=0.0001) was observed with the Shinshu grading system of resection. In addition, a Ki-67% marker for proliferation less than 15% (p=0.029), absence of certain radiological features including heterogeneous enhancement, cyst formation and peritumoral edema (p=0.006), and repeat surgery for recurrent meningioma was associated with better survival (p=0.014). However, radiosurgery did not have a beneficial role in the treatment of recurrence of atypical meningioma. The Simpson grading system is the primary predictor of recurrence of WHO grade II meningioma after resection. In addition, certain pathological and radiological features need to be considered as possible factors of recurrence after resection. Lastly, depending on the likely risks and surgical morbidity, repeat surgical resection should be performed for recurrent atypical meningioma. Published by Elsevier Ltd.

Entities:  

Keywords:  Atypical meningioma; Outcome; Predictors; Recurrence

Mesh:

Year:  2016        PMID: 27427214     DOI: 10.1016/j.jocn.2016.02.021

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  15 in total

1.  Meningioma recurrence rates following treatment: a systematic analysis.

Authors:  Victor Lam Shin Cheung; Albert Kim; Arjun Sahgal; Sunit Das
Journal:  J Neurooncol       Date:  2017-11-15       Impact factor: 4.130

2.  TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.

Authors:  Annamaria Biczok; Theo Kraus; Bogdana Suchorska; Nicole A Terpolilli; Jun Thorsteinsdottir; Armin Giese; Joerg C Tonn; Christian Schichor
Journal:  J Neurooncol       Date:  2018-05-28       Impact factor: 4.130

Review 3.  Brachytherapy for central nervous system tumors.

Authors:  Evan D Bander; Jonathan P S Knisely; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2022-05-11       Impact factor: 4.130

4.  Clinical features, radiological findings, and treatment outcomes of high-grade lateral ventricular meningiomas: a report of 26 cases.

Authors:  Yong Jiang; Liang Lv; Jiuhong Li; Weichao Ma; Cheng Chen; Peizhi Zhou; Shu Jiang
Journal:  Neurosurg Rev       Date:  2019-01-16       Impact factor: 3.042

5.  Extent of resection and survival outcomes in World Health Organization grade II meningiomas.

Authors:  Pranay Soni; Mark A Davison; Jianning Shao; Arbaz Momin; Diana Lopez; Lilyana Angelov; Gene H Barnett; Joung H Lee; Alireza M Mohammadi; Varun R Kshettry; Pablo F Recinos
Journal:  J Neurooncol       Date:  2020-11-17       Impact factor: 4.130

6.  Peritumoral edema correlates with mutational burden in meningiomas.

Authors:  Corey M Gill; Joshua Loewenstern; John W Rutland; Hanane Arib; Margaret Pain; Melissa Umphlett; Yayoi Kinoshita; Russell B McBride; Joshua Bederson; Michael Donovan; Robert Sebra; Mary Fowkes; Raj K Shrivastava
Journal:  Neuroradiology       Date:  2020-08-12       Impact factor: 2.804

7.  Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.

Authors:  Masahiro Yamamoto; Tomomi Sanomachi; Shuhei Suzuki; Hiroyuki Uchida; Hajime Yonezawa; Nayuta Higa; Tomoko Takajo; Yuki Yamada; Asuka Sugai; Keita Togashi; Shizuka Seino; Masashi Okada; Yukihiko Sonoda; Hirofumi Hirano; Koji Yoshimoto; Chifumi Kitanaka
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

8.  Recurred Intracranial Meningioma: A Retrospective Analysis for Treatment Outcome and Prognostic Factor.

Authors:  Hyun-Seung Ryu; Kyung-Sub Moon; Kyung-Hwa Lee; Woo-Youl Jang; Tae-Young Jung; In-Young Kim; Shin Jung
Journal:  Brain Tumor Res Treat       Date:  2017-11-03

9.  The Prognostic Value of Pretreatment Gallium-68 DOTATATE Positron Emission Tomography/Computed Tomography in Irradiated Non-benign Meningioma.

Authors:  Maciej J Pelak; Andrea d'Amico
Journal:  Indian J Nucl Med       Date:  2019 Oct-Dec

10.  Clinical Factors and Outcomes of Atypical Meningioma: A Population-Based Study.

Authors:  Gui-Jun Zhang; Xiao-Yin Liu; Chao You
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.